These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 8691454)

  • 1. Novel 3,7-diheterabicyclo[3.3.1]nonanes that possess predominant class III antiarrhythmic activity in 1-4 day post infarction dog models: X-ray diffraction analysis of 3-[4-(1H-imidazol-1-yl)benzoyl]-7-isopropyl-3,7-diazabicyclo[3.3.1]nona ne dihydroperchlorate.
    Garrison GL; Berlin KD; Scherlag BJ; Lazzara R; Patterson E; Fazekas T; Sangiah S; Chen CL; Schubot FD; van der Helm D
    J Med Chem; 1996 Jun; 39(13):2559-70. PubMed ID: 8691454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, conformational analysis, and antiarrhythmic properties of 7-benzyl-3-thia-7-azabicyclo[3.3.1]nonan-9-one, 7-benzyl-3-thia-7-azabicyclo[3.3.1]nonane hydroperchlorate, and 7-benzyl-9-phenyl-3-thia-7-azabicyclo[3.3.1]nonan-9-ol hydroperchlorate and derivatives: single-crystal X-ray diffraction analysis and evidence for chair-chair and chair-boat conformers in the solid state.
    Bailey BR; Berlin KD; Holt EM; Scherlag BJ; Lazzara R; Brachmann J; van der Helm D; Powell DR; Pantaleo NS; Ruenitz PC
    J Med Chem; 1984 Jun; 27(6):758-67. PubMed ID: 6737418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electrophysiological and inotropic characterization of a novel class III antiarrhythmic agent, GLG-V-13, in the mammalian heart.
    Fazekas T; Carlsson L; Scherlag BJ; Mabo P; Poty H; Palmer M; Patterson E; Berlin KD; Garrison GL; Lazzara R
    J Cardiovasc Pharmacol; 1996 Aug; 28(2):182-91. PubMed ID: 8856472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3,8-diazabicyclo--[3.2.1]-octane derivatives as analogues of ambasilide, a Class III antiarrhythmic agent.
    Villa S; Barlocco D; Cignarella G; Papp GJ; Baláti B; Takács J; Varró A; Borosy A; Keserû K; Mátyus P
    Eur J Med Chem; 2001 Jun; 36(6):495-506. PubMed ID: 11525840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and plasma protein binding of the new potent class III antiarrhythmic agent 3-[4-(1H-imidazol-1-yl)benzoyl]-7-isopropyl-3, 7-diazabicyclo[3.3.1]nonane dihydroperchlorate.
    Chen CL; Sangiah S; Roder JD; Chen H; Berlin KD; Garrison GL; Scherlag BJ; Lazzara R
    Arzneimittelforschung; 1995 Jun; 45(6):670-5. PubMed ID: 7646568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The comparative antiarrhythmic and proarrhythmic activity of a 3,7-diheterobicyclo[3.3.1]nonane, BRB-I-28, and lidocaine in the 1-4-day-old infarcted dog heart.
    Fazekas T; Scherlag BJ; Mabo P; Berlin KD; Garrison GL; Chen CL; Sangiah S; Patterson E; Lazzara R
    Acta Physiol Hung; 1993; 81(3):289-99. PubMed ID: 8197884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Electrophysiological characterization of a novel class III antiarrhythmic agent, GLG-V-13 in the mammalian heart.
    Fazekas T; Scherlag BJ; Carlsson L; Mabo P; Patterson E; Berlin KD; Lazzara R
    Acta Physiol Hung; 1995; 83(1):13-30. PubMed ID: 7660832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and antiarrhythmic activity of novel 3-alkyl-1-[omega-[4-[(alkylsulfonyl)amino]phenyl]-omega- hydroxyalkyl]-1H-imidazolium salts and related compounds. 2.
    Lis R; Davey DD; Morgan TK; Lumma WC; Wohl RA; Jain VK; Wan CN; Argentieri TM; Sullivan ME; Cantor EH
    J Med Chem; 1987 Dec; 30(12):2303-9. PubMed ID: 3681900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary acute and subchronic toxicity studies of GLG-V-13, a novel class III antiarrhythmic agent, in mice.
    Chen CL; Chandra SA; Kim S; Sangiah S; Chen H; Roder JD; Qualls CW; Garrison GL; Cowell RL; Berlin KD; Scherlag BJ; Lazzara R
    Arzneimittelforschung; 2000 Jan; 50(1):31-8. PubMed ID: 10683713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis, pharmacological characterization, and quantitative structure-activity relationship analyses of 3,7,9,9-tetraalkylbispidines: derivatives with specific bradycardic activity.
    Schön U; Antel J; Brückner R; Messinger J; Franke R; Gruska A
    J Med Chem; 1998 Jan; 41(3):318-31. PubMed ID: 9464363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Na+ channel blockers vs class III antiarrhythmic drugs in treating sustained ventricular tachycardia: reversing and preventing as different electrophysiological mechanisms.
    Masotti CS; Pierangeli A
    Panminerva Med; 1999 Dec; 41(4):295-306. PubMed ID: 10705709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and antiarrhythmic properties of novel 3-selena-7-azabicyclo[3.3.1]nonanes and derivatives. Single-crystal X-ray diffraction analysis of 7-benzyl-3-selena-7-azabicyclo[3.3.1]nonan-9-one and 7-benzyl-3-selena-7-azabicyclo[3.3.1]nonane hydroperchlorate.
    Thompson MD; Smith GS; Berlin KD; Holt EM; Scherlag BJ; van der Helm D; Muchmore SW; Fidelis KA
    J Med Chem; 1987 May; 30(5):780-8. PubMed ID: 3572967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of RS-2135, a novel class I antiarrhythmic agent, on sustained ventricular tachycardia after coronary embolization in conscious dogs.
    Yorikane R; Mizuno H; Itoh Y; Miyake S; Koike H
    J Cardiovasc Pharmacol; 1994 Jul; 24(1):28-36. PubMed ID: 7521486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872.
    Bril A; Gout B; Bonhomme M; Landais L; Faivre JF; Linee P; Poyser RH; Ruffolo RR
    J Pharmacol Exp Ther; 1996 Feb; 276(2):637-46. PubMed ID: 8632331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic interaction between class I antiarrhythmic drugs and halothane in depressant effects on ventricular activation in a canine myocardial infarction model.
    Hashimoto H; Imamura S; Ikeda K; Nakashima M
    Biol Pharm Bull; 1994 Mar; 17(3):449-53. PubMed ID: 8019516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of AHR-12234 on cardiac transmembrane action potentials, in situ cardiac electrophysiology and experimental models for arrhythmias.
    Wu KM; Proakis AG; Hunter TL; Shanklin JR
    Arch Int Pharmacodyn Ther; 1989; 301():131-50. PubMed ID: 2624512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiarrhythmic and electrophysiologic effects of bepridil in chronically infarcted conscious dogs.
    Lynch JJ; Montgomery DG; Ventura A; Lucchesi BR
    J Pharmacol Exp Ther; 1985 Jul; 234(1):72-80. PubMed ID: 3874285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiarrhythmic efficacy of a new class III agent, UK-68,798, during chronic myocardial infarction: evaluation using three-dimensional mapping.
    Zuanetti G; Corr PB
    J Pharmacol Exp Ther; 1991 Jan; 256(1):325-34. PubMed ID: 1988663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and antiarrhythmic activity of novel 3-alkyl-1-[omega-[4-[(alkylsulfonyl)amino]phenyl]-omega- hydroxyalkyl]-1H-imidazolium salts and related compounds.
    Lis R; Morgan TK; DeVita RJ; Davey DD; Lumma WC; Wohl RA; Diamond J; Wong SS; Sullivan ME
    J Med Chem; 1987 Apr; 30(4):696-704. PubMed ID: 3560162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and study on 2,4,6,8-tetraaryl- 3,7-diazabicyclo[3.3.1]nonanes and their derivatives.
    Vijayakumar V; Sundaravadivelu M
    Magn Reson Chem; 2005 Jun; 43(6):479-82. PubMed ID: 15809985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.